Homology Medicines Stock Forecast, Price & News

-0.14 (-2.15 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume257,497 shs
Average Volume436,203 shs
Market Capitalization$363.03 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FIXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

Homology Medicines logo

About Homology Medicines

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase I/II pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II. Homology Medicines, Inc. was incorporated in 2015 and is based in Bedford, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.05 out of 5 stars

Medical Sector

486th out of 2,223 stocks

Pharmaceutical Preparations Industry

244th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Homology Medicines (NASDAQ:FIXX) Frequently Asked Questions

Is Homology Medicines a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Homology Medicines stock.
View analyst ratings for Homology Medicines
or view top-rated stocks.

What stocks does MarketBeat like better than Homology Medicines?

Wall Street analysts have given Homology Medicines a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Homology Medicines wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Homology Medicines' next earnings date?

Homology Medicines is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Homology Medicines

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings data on Thursday, May, 6th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.59. The business had revenue of $29.31 million for the quarter, compared to analysts' expectations of $0.78 million. Homology Medicines had a negative trailing twelve-month return on equity of 49.59% and a negative net margin of 300.57%.
View Homology Medicines' earnings history

How has Homology Medicines' stock price been impacted by COVID-19 (Coronavirus)?

Homology Medicines' stock was trading at $17.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, FIXX shares have decreased by 64.5% and is now trading at $6.36.
View which stocks have been most impacted by COVID-19

What price target have analysts set for FIXX?

4 brokerages have issued 1-year target prices for Homology Medicines' stock. Their forecasts range from $14.00 to $34.00. On average, they expect Homology Medicines' share price to reach $24.20 in the next twelve months. This suggests a possible upside of 280.5% from the stock's current price.
View analysts' price targets for Homology Medicines
or view top-rated stocks among Wall Street analysts.

Who are Homology Medicines' key executives?

Homology Medicines' management team includes the following people:
  • Dr. Arthur O. Tzianabos, Pres, CEO & Director (Age 58, Pay $885.96k)
  • Mr. W. Bradford Smith, CFO & Treasurer (Age 65, Pay $582.38k)
  • Dr. Albert Seymour Ph.D., Chief Scientific Officer (Age 53, Pay $607.58k)
  • Dr. Saswati Chatterjee, Co-Founder & Chair of Scientific Advisory Board
  • Mr. Timothy P. Kelly, Chief Operating Officer (Age 52)
  • Dr. Paul Alloway J.D., Ph.D., Sr. VP & Gen. Counsel
  • Ms. Theresa McNeely, Chief Communications Officer & Patient Advocate (Age 57)
  • Ms. Melissa Gelormini, VP of HR
  • Dr. Gabriel M. Cohn M.B.A., M.D., Chief Medical Officer (Age 62)
  • Mr. Michael Blum M.B.A., Sr. VP of Commercial

Who are some of Homology Medicines' key competitors?

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), (CGC) and Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

(FIXX) raised $100 million in an IPO on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What is Homology Medicines' stock symbol?

Homology Medicines trades on the NASDAQ under the ticker symbol "FIXX."

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by a variety of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (0.10%). Company insiders that own Homology Medicines stock include Albert Seymour, Arthur Tzianabos, James E Flynn, Kush Parmar, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends for Homology Medicines

Which institutional investors are buying Homology Medicines stock?

FIXX stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P..
View insider buying and selling activity for Homology Medicines
or or view top insider-buying stocks.

How do I buy shares of Homology Medicines?

Shares of FIXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Homology Medicines' stock price today?

One share of FIXX stock can currently be purchased for approximately $6.36.

How much money does Homology Medicines make?

Homology Medicines has a market capitalization of $363.03 million and generates $2.70 million in revenue each year. The company earns $-128,690,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How many employees does Homology Medicines have?

Homology Medicines employs 205 workers across the globe.

What is Homology Medicines' official website?

The official website for Homology Medicines is

Where are Homology Medicines' headquarters?

Homology Medicines is headquartered at ONE PATRIOTS PARK, BEDFORD MA, 01730.

How can I contact Homology Medicines?

Homology Medicines' mailing address is ONE PATRIOTS PARK, BEDFORD MA, 01730. The company can be reached via phone at 781-301-7277.

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.